While this initially seems counterintuitive to the data presented here, FOXP1 can act as either an oncogene or a tumor suppressor depending on the cellular context and, thus, this does not exclude the potential for FOXP1 expression to predict a poor response to immune checkpoint inhibition in DLBCL patients. Here, FOXP1 is linked to diffuse large B-cell lymphoma.